$3.85
-0.34 (-8.11%)
Open$4.04
Previous Close$4.19
Day High$4.66
Day Low$3.80
52W High$40.37
52W Low$2.96
Volume—
Avg Volume10.35M
Market Cap244.10M
P/E Ratio—
EPS$-2.31
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,521.8% upside
Current
$3.85
$3.85
Target
$62.44
$62.44
$34.96
$62.44 avg
$82.04
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.52M | 187.20M | 168.99M |
| Net Income | -55,455,340 | 36.18M | 32.84M |
| Profit Margin | -181.7% | 19.3% | 19.4% |
| EBITDA | -56,521,974 | 59.64M | 51.36M |
| Free Cash Flow | — | 19.67M | 27.43M |
| Rev Growth | +352.7% | +21.4% | +1.7% |
| Debt/Equity | 0.02 | 1.29 | 1.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |